Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
Hodgkin Lymphoma (HL) is one of the hematological malignancies where the inflammatory process is quite high, immunotherapy agents are frequently used and successful results are obtained. We aimed to show real-life data on health outcomes in adult patients withrecurrent or refractory HL who received...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Turaz Bilim
2020-12-01
|
| Series: | Medicine Science |
| Subjects: | |
| Online Access: | http://www.ejmanager.com/fulltextpdf.php?mno=119705 |